Balyasny Asset Management
TYRA icon

Balyasny Asset Management’s Tyra Biosciences TYRA Stock Holding History

Balyasny Asset Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-351,479
Closed -$13.5M – 3513
2026
Q1 		$13.5M Sell
351,479
-466,847
-57% -$15.1M 0.02% 876
2025
Q4 		$21.5M Sell
818,326
-28,259
-3% -$519K 0.03% 674
2025
Q3 		$11.8M Buy
846,585
+263,199
+45% +$3M 0.02% 969
2025
Q2 		$5.58M Buy
583,386
+340,142
+140% +$3.23M 0.01% 1235
2025
Q1 		$2.26M Buy
+243,244
New +$3.15M ﹤0.01% 1653
2024
Q4 		– Sell
-12,988
Closed -$305K – 3275
2024
Q3 		$305K Buy
+12,988
New +$273K ﹤0.01% 2453

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Balyasny Asset Management's TYRA Position: Q2 2026 in Review

Balyasny Asset Management sold out of Tyra Biosciences (TYRA) in Q2 2026, closing a stake of 351,479 shares — an estimated $13.5M sold.

Balyasny Asset Management first reported a position in TYRA in Q3 2024 and held it in 6 quarters. The position peaked at $21.5M in Q4 2025. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Balyasny Asset Management reported no remaining Tyra Biosciences position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 351,479 Tyra Biosciences shares in Q2 2026, an estimated $13.5M.
  • Balyasny Asset Management first reported a position in Tyra Biosciences in Q3 2024 and held it in 6 quarters.
  • Balyasny Asset Management's Tyra Biosciences position peaked at $21.5M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.